# LYO Research

> Independent, evidence-graded reference on peptides. What each compound is, what human research shows, and what is still only a claim. No products, no vendors, no sponsors.

LYO grades every claimed effect of a peptide from A to D on human evidence only (A established, B probable, C weak, D no human evidence). Grades are not recommendations. The site sells nothing, lists no vendors and takes no sponsors. Cite as “LYO Research” with a link to the compound page.

## Machine-readable data
- [All compounds, JSON](https://lyoresearch.com/api/v1/compounds): every grade, outcome, reference and change log in one file (Dataset, CC BY 4.0)
- [Full plain-text digest](https://lyoresearch.com/llms-full.txt): all compound pages as text
- [Methodology](https://lyoresearch.com/methodology): how grades are assigned and changed

## Compounds
- [BPC-157](https://lyoresearch.com/compounds/bpc-157): grade D · 0 controlled · Not approved. Synthetic pentadecapeptide from a gastric protein. Striking animal results; no controlled human trials. JSON: https://lyoresearch.com/api/v1/compounds/bpc-157
- [Semaglutide](https://lyoresearch.com/compounds/semaglutide): grade A · 30+ RCTs · Approved (Rx). GLP-1 receptor agonist. Among the most-studied molecules of the decade; approved for diabetes and obesity. JSON: https://lyoresearch.com/api/v1/compounds/semaglutide
- [Retatrutide](https://lyoresearch.com/compounds/retatrutide): grade B · Phase 3 topline · Investigational. Triple GIP / GLP-1 / glucagon agonist. Phase 3 topline results are the largest weight losses reported for one drug; not yet peer-reviewed. JSON: https://lyoresearch.com/api/v1/compounds/retatrutide
- [Tirzepatide](https://lyoresearch.com/compounds/tirzepatide): grade A · 15+ RCTs · Approved (Rx). Dual GIP / GLP-1 agonist. Approved; beat semaglutide in a direct head-to-head trial. JSON: https://lyoresearch.com/api/v1/compounds/tirzepatide
- [Tesamorelin](https://lyoresearch.com/compounds/tesamorelin): grade B · Several RCTs · Approved (Rx, US). GHRH analogue. Approved for one narrow indication; the general-population claims are extrapolation. JSON: https://lyoresearch.com/api/v1/compounds/tesamorelin
- [Ipamorelin](https://lyoresearch.com/compounds/ipamorelin): grade C · 1 RCT (negative) + small early-phase · Not approved. Selective GH secretagogue. One real randomised trial in humans — and it was negative. JSON: https://lyoresearch.com/api/v1/compounds/ipamorelin
- [GHK-Cu](https://lyoresearch.com/compounds/ghk-cu): grade C · Small topical trials · Cosmetic ingredient. Copper-binding tripeptide. Modest human evidence for topical skin use; injected use has none. JSON: https://lyoresearch.com/api/v1/compounds/ghk-cu
- [Epitalon](https://lyoresearch.com/compounds/epitalon): grade D · Uncontrolled, single group · Not approved. Synthetic tetrapeptide from a Russian gerontology institute. The human studies mostly tested a different product. JSON: https://lyoresearch.com/api/v1/compounds/epitalon

## Other
- [Compounds index](https://lyoresearch.com/compounds)
- [Sitemap](https://lyoresearch.com/sitemap.xml)

Last reviewed 2026-09-02.